At a glance
- Vasopressin is an FDA-approved drug, marketed as Vasostrict, Vasopressin (first approval: April 17, 2014).
- PubMed lists 4,366 publications mentioning it, including 918 randomized controlled trials and 944 animal-only studies.
- ClinicalTrials.gov lists 344 registered studies testing it (58 active).
- FDA's adverse event system (FAERS) holds 4,953 reports mentioning it; 4,769 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA204485 | VASOSTRICT | Approved, marketed | April 17, 2014 | PH HEALTH |
| NDA212593 | VASOPRESSIN | Approved, marketed | August 3, 2020 | AM REGENT |
| ANDA211538 | VASOPRESSIN | Approved, discontinued | December 15, 2021 | EAGLE PHARMS |
| ANDA211857 | VASOPRESSIN | Approved, marketed | July 18, 2022 | AMPHASTAR PHARMS INC |
| ANDA212944 | VASOPRESSIN | Approved, marketed | August 5, 2022 | AMNEAL |
| ANDA214314 | VASOPRESSIN | Approved, marketed | August 15, 2022 | EUGIA PHARMA |
| ANDA213206 | VASOPRESSIN | Approved, marketed | May 26, 2023 | FRESENIUS KABI USA |
| NDA217569 | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Approved, marketed | September 29, 2023 | BAXTER HLTHCARE CORP |
| ANDA217987 | VASOPRESSIN | Approved, marketed | December 6, 2023 | CIPLA |
| ANDA216963 | VASOPRESSIN, VASOPRESSIN IN DEXTROSE 5% | Approved, marketed | February 9, 2024 | GLAND |
| ANDA213988 | VASOPRESSIN, VASOPRESSIN IN DEXTROSE 5% | Approved, marketed | May 8, 2024 | DR REDDYS |
| NDA217766 | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Approved, marketed | July 11, 2024 | LONG GROVE PHARMS |
| ANDA212068 | VASOPRESSIN | Approved, marketed | May 6, 2026 | SANDOZ |
| ANDA212069 | VASOPRESSIN | Approved, marketed | May 6, 2026 | SANDOZ |
| ANDA212945 | VASOPRESSIN | Tentative approval | — | AMNEAL EU LTD |
| NDA003402 | PITRESSIN TANNATE | Approved, discontinued | — | PARKE DAVIS |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Effects of perfusion-guided permissive hypotension and early vasopressin initiation in adults with septic shock: protocol for a multicentre 2×2 factorial randomised controlled trial in Japanese intensive care units.
- Hypotonic Hyponatremia: Diagnosis and Management.
- Heterogeneous cardiovascular responses to acute mean arterial pressure augmentation in septic shock: the role of ventriculo-arterial coupling and venous return.
- Hemodynamic Patterns Relative to Vasopressin Initiation and Subsequent Septic Shock Progression in Children: A Retrospective Cohort, 2020-2023.
- Proenkephalin A and Heterogeneity of Hydrocortisone Treatment Effect in Septic Shock: A Post Hoc Analysis of the VANISH Trial.
- Vasopressors Combination Therapy (Norepinephrine Plus Vasopressin Receptor Agonists) Improve Septic Shock Outcome: A Systematic Review and Meta-Analysis.
- Effect of Vasopressin Infusion Rate on Vancomycin Dose Adjustment in Pediatric Central Diabetes Insipidus: Grand Round/A Case Study.
- Toward very early vasopressin use in septic shock: observational data accumulate but trial evidence still lacking.
- Prognostic discrimination of SOFA-2 vs. SOFA-1 and incremental information from cardiovascular scoring and vasoactive support intensity in patients with sepsis receiving early vasoactive therapy.
- Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: Research Summary.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 344
- Active
- 58
- With posted results
- 62
Conditions studied
Show 40 more studies
All 344 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 4,953
- Serious
- 4,769
- With death outcome
- 1,986
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
- VASOPRESSIN
- VASOPRESSIN
- VASOPRESSIN
- Vasostrict
- Vasostrict
- VASOPRESSIN
- VASOPRESSIN
- Vasopressin
- VASOPRESSIN
- Vasopressin in 0.9% Sodium Chloride
- vasopressin
- Vasopressin
- VASOPRESSIN
- Vasopressin in 0.9% Sodium Chloride
- VASOPRESSIN
- Vasopressin
- Vasopressin
- vasopressin
- vasopressin
- VASOPRESSIN
- VASOPRESSIN
- Vasostrict
- Vasostrict
- Vasopressin
- VASOPRESSIN
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.